Literature DB >> 21620547

Development and validation of a self-assessment tool for albuminuria: results from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Paul Muntner1, Mark Woodward, April P Carson, Suzanne E Judd, Emily B Levitan, Devin M Mann, William McClellan, David G Warnock.   

Abstract

BACKGROUND: The prevalence of albuminuria in the general population is high, but awareness of it is low. Therefore, we sought to develop and validate a self-assessment tool that allows individuals to estimate their probability of having albuminuria. STUDY
DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: The population-based Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study for model development and the National Health and Nutrition Examination Survey (NHANES) 1999-2004 for model validation. US adults 45 years or older in the REGARDS Study (n = 19,697) and NHANES 1999-2004 (n = 7,168). PREDICTOR: Candidate items for the self-assessment tool were collected using a combination of interviewer- and self-administered questionnaires. OUTCOME: Albuminuria was defined as a urinary albumin to urinary creatinine ratio ≥30 mg/g in spot samples.
RESULTS: 8 items were included in the self-assessment tool (age, race, sex, current smoking, self-rated health, and self-reported history of diabetes, hypertension, and stroke). These items provided a C statistic of 0.709 (95% CI, 0.699-0.720) and good model fit (Hosmer-Lemeshow χ(2)P = 0.49). In the external validation data set, the C statistic for discriminating individuals with and without albuminuria using the self-assessment tool was 0.714. Using a threshold of ≥10% probability of albuminuria from the self-assessment tool, 36% of US adults 45 years or older in NHANES 1999-2004 would test positive and be recommended for screening. Sensitivity, specificity, and positive and negative predictive values for albuminuria associated with a probability ≥10% were 66%, 68%, 23%, and 93%, respectively. LIMITATIONS: Repeated urine samples were not available to assess the persistency of albuminuria.
CONCLUSIONS: 8 self-report items provide good discrimination for the probability of having albuminuria. This tool may encourage individuals with a high probability to request albuminuria screening.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21620547      PMCID: PMC3144301          DOI: 10.1053/j.ajkd.2011.01.027

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  40 in total

1.  Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation.

Authors:  W F Keane; G Eknoyan
Journal:  Am J Kidney Dis       Date:  1999-05       Impact factor: 8.860

2.  Self-rated health showed a graded association with frequently used biomarkers in a large population sample.

Authors:  Marja Jylhä; Stefano Volpato; Jack M Guralnik
Journal:  J Clin Epidemiol       Date:  2006-03-15       Impact factor: 6.437

3.  Screening, monitoring, and treatment of albuminuria: Public health perspectives.

Authors:  Paul E de Jong; Gary C Curhan
Journal:  J Am Soc Nephrol       Date:  2006-07-06       Impact factor: 10.121

4.  Screening for nephropathy and antiangiotensin use among diabetic patients in an academic community medical center.

Authors:  Lawrence A Frazee; Seyhoon Samandari; Natthavat Tanphaichitr; Claire C Bourguet; Eugene W Pfister
Journal:  Am J Ther       Date:  2006 Jan-Feb       Impact factor: 2.688

5.  Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure.

Authors:  L A Sechi; L Zingaro; C Catena; A Perin; S De Marchi; E Bartoli
Journal:  Kidney Int       Date:  1999-09       Impact factor: 10.612

6.  Decision curve analysis: a novel method for evaluating prediction models.

Authors:  Andrew J Vickers; Elena B Elkin
Journal:  Med Decis Making       Date:  2006 Nov-Dec       Impact factor: 2.583

7.  Prevalence of chronic kidney disease in the United States.

Authors:  Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

8.  Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study.

Authors:  Marc M H Hermans; Ronald Henry; Jacqueline M Dekker; Jeroen P Kooman; Piet J Kostense; Giel Nijpels; Robert J Heine; Coen D A Stehouwer
Journal:  J Am Soc Nephrol       Date:  2007-04-25       Impact factor: 10.121

9.  Association of cigarette smoking with albuminuria in the United States: the third National Health and Nutrition Examination Survey.

Authors:  Susan L Hogan; Suma Vupputuri; Xuguang Guo; Jianwen Cai; Romulo E Colindres; Gerardo Heiss; Josef Coresh
Journal:  Ren Fail       Date:  2007       Impact factor: 2.606

Review 10.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

View more
  2 in total

1.  Validation of an Albuminuria Self-assessment Tool in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Rikki M Tanner; Mark Woodward; Carmen Peralta; David G Warnock; Orlando Gutiérrez; Daichi Shimbo; Holly Kramer; Ronit Katz; Paul Muntner
Journal:  Ethn Dis       Date:  2015-11-05       Impact factor: 1.847

2.  Pediatric Immunization Practices in Nephrotic Syndrome: An Assessment of Provider and Parental Knowledge.

Authors:  Cheryl L Tran; David T Selewski; Gia J Oh; Jonathan P Troost; Susan F Massengill; Samhar I Al-Akash; Shefali Mahesh; Rasheda Amin; Isa F Ashoor; Rahul Chanchlani; Mahmoud Kallash; Robert P Woroniecki; Debbie S Gipson
Journal:  Front Pediatr       Date:  2021-02-05       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.